egfr cell signalling 4267 1 1000  (Cell Signaling Technology Inc)


Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc egfr cell signalling 4267 1 1000
    Egfr Cell Signalling 4267 1 1000, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr cell signalling 4267 1 1000/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr cell signalling 4267 1 1000 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    anti p egfr tyr1068  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc anti p egfr tyr1068
    Anti P Egfr Tyr1068, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p egfr tyr1068/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti p egfr tyr1068 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    egfr  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc egfr
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> <t>AKT</t> and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2024-06
    86/100 stars

    Images

    1) Product Images from "Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway"

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    Journal: International Journal of Ophthalmology

    doi: 10.18240/ijo.2024.06.05

    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Techniques Used: MTT Assay, Labeling, Migration, Wound Healing Assay, Western Blot

    A, B: ARPE-19 cells were treated with erlotinib (0, 5, 10, 20, and 50 µmol/L) for 24h. The expreesion of total EGFR and AKT proteins were measured by Western blot. aP<0.05, bP<0.01. C: After treatment with 50 µmol/L erlotinib for 24h, EGFR, F-actin, and nucleus in ARPE-19 cells were measured by immunofluorescence staining, scale bar: 50 µm. APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: A, B: ARPE-19 cells were treated with erlotinib (0, 5, 10, 20, and 50 µmol/L) for 24h. The expreesion of total EGFR and AKT proteins were measured by Western blot. aP<0.05, bP<0.01. C: After treatment with 50 µmol/L erlotinib for 24h, EGFR, F-actin, and nucleus in ARPE-19 cells were measured by immunofluorescence staining, scale bar: 50 µm. APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; DAPI: Diamidino-2-phenylindole.

    Techniques Used: Western Blot, Immunofluorescence, Staining

    ARPE-19 cells were pretreated by erlotinib (20 µmol/L) for 12h and then stimulated with 100 ng/mL of EGF for 24h. A, B: BrdU staining assay was used to test cellular proliferation, scale bar: 50 µm, n=3. C: Cellular viability was sized by MTT assay, n=8. D, E: Cellular migration was tested by the wound healing assay, scale bar: 200 µm, n=3. F, G: ARPE-19 cells were pretreated with 20 µmol/L erlotinib for 12h and then treated with EGF (100 ng/mL) for 15min. Western blotting was used to detected EGFR/AKT signaling pathway proteins expressions. H, I: After pretreatment with 20 µmol/L erlotinib for 12h, ARPE-19 cells were treated with EGF (100 ng/mL) for 24h. N-cadherin, α-SMA and vimentin proteins were determined by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; α-SMA: α-smooth muscle actin; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: ARPE-19 cells were pretreated by erlotinib (20 µmol/L) for 12h and then stimulated with 100 ng/mL of EGF for 24h. A, B: BrdU staining assay was used to test cellular proliferation, scale bar: 50 µm, n=3. C: Cellular viability was sized by MTT assay, n=8. D, E: Cellular migration was tested by the wound healing assay, scale bar: 200 µm, n=3. F, G: ARPE-19 cells were pretreated with 20 µmol/L erlotinib for 12h and then treated with EGF (100 ng/mL) for 15min. Western blotting was used to detected EGFR/AKT signaling pathway proteins expressions. H, I: After pretreatment with 20 µmol/L erlotinib for 12h, ARPE-19 cells were treated with EGF (100 ng/mL) for 24h. N-cadherin, α-SMA and vimentin proteins were determined by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; α-SMA: α-smooth muscle actin; DAPI: Diamidino-2-phenylindole.

    Techniques Used: BrdU Staining, MTT Assay, Migration, Wound Healing Assay, Western Blot

    A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Techniques Used: Control, Transfection, Western Blot, MTT Assay, Labeling, Migration, Wound Healing Assay, Small Interfering RNA

    A, B: After EGFR-siRNA transfections, ARPE-19 cells were treated without or with 100 ng/mL of EGF for 24h. N-cadherin, α-SMA and vimentin proteins were detected by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; APRE-19: Adult retinal pigment epithelial cell line-19; siRNA: Small interfering RNA; α-SMA: α-smooth muscle actin.
    Figure Legend Snippet: A, B: After EGFR-siRNA transfections, ARPE-19 cells were treated without or with 100 ng/mL of EGF for 24h. N-cadherin, α-SMA and vimentin proteins were detected by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; APRE-19: Adult retinal pigment epithelial cell line-19; siRNA: Small interfering RNA; α-SMA: α-smooth muscle actin.

    Techniques Used: Transfection, Western Blot, Small Interfering RNA

    phosphorylated egfr p egfr  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc phosphorylated egfr p egfr
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Phosphorylated Egfr P Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated egfr p egfr/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phosphorylated egfr p egfr - by Bioz Stars, 2024-06
    86/100 stars

    Images

    1) Product Images from "Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway"

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    Journal: International Journal of Ophthalmology

    doi: 10.18240/ijo.2024.06.05

    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Techniques Used: MTT Assay, Labeling, Migration, Wound Healing Assay, Western Blot

    A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Techniques Used: Control, Transfection, Western Blot, MTT Assay, Labeling, Migration, Wound Healing Assay, Small Interfering RNA

    phosphorylated egfr p egfr  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc phosphorylated egfr p egfr
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Phosphorylated Egfr P Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated egfr p egfr/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phosphorylated egfr p egfr - by Bioz Stars, 2024-06
    86/100 stars

    Images

    1) Product Images from "Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway"

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    Journal: International Journal of Ophthalmology

    doi: 10.18240/ijo.2024.06.05

    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Techniques Used: MTT Assay, Labeling, Migration, Wound Healing Assay, Western Blot

    A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Techniques Used: Control, Transfection, Western Blot, MTT Assay, Labeling, Migration, Wound Healing Assay, Small Interfering RNA

    egfr  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc egfr
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> <t>AKT</t> and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2024-06
    86/100 stars

    Images

    1) Product Images from "Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway"

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    Journal: International Journal of Ophthalmology

    doi: 10.18240/ijo.2024.06.05

    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Techniques Used: MTT Assay, Labeling, Migration, Wound Healing Assay, Western Blot

    A, B: ARPE-19 cells were treated with erlotinib (0, 5, 10, 20, and 50 µmol/L) for 24h. The expreesion of total EGFR and AKT proteins were measured by Western blot. aP<0.05, bP<0.01. C: After treatment with 50 µmol/L erlotinib for 24h, EGFR, F-actin, and nucleus in ARPE-19 cells were measured by immunofluorescence staining, scale bar: 50 µm. APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: A, B: ARPE-19 cells were treated with erlotinib (0, 5, 10, 20, and 50 µmol/L) for 24h. The expreesion of total EGFR and AKT proteins were measured by Western blot. aP<0.05, bP<0.01. C: After treatment with 50 µmol/L erlotinib for 24h, EGFR, F-actin, and nucleus in ARPE-19 cells were measured by immunofluorescence staining, scale bar: 50 µm. APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; DAPI: Diamidino-2-phenylindole.

    Techniques Used: Western Blot, Immunofluorescence, Staining

    ARPE-19 cells were pretreated by erlotinib (20 µmol/L) for 12h and then stimulated with 100 ng/mL of EGF for 24h. A, B: BrdU staining assay was used to test cellular proliferation, scale bar: 50 µm, n=3. C: Cellular viability was sized by MTT assay, n=8. D, E: Cellular migration was tested by the wound healing assay, scale bar: 200 µm, n=3. F, G: ARPE-19 cells were pretreated with 20 µmol/L erlotinib for 12h and then treated with EGF (100 ng/mL) for 15min. Western blotting was used to detected EGFR/AKT signaling pathway proteins expressions. H, I: After pretreatment with 20 µmol/L erlotinib for 12h, ARPE-19 cells were treated with EGF (100 ng/mL) for 24h. N-cadherin, α-SMA and vimentin proteins were determined by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; α-SMA: α-smooth muscle actin; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: ARPE-19 cells were pretreated by erlotinib (20 µmol/L) for 12h and then stimulated with 100 ng/mL of EGF for 24h. A, B: BrdU staining assay was used to test cellular proliferation, scale bar: 50 µm, n=3. C: Cellular viability was sized by MTT assay, n=8. D, E: Cellular migration was tested by the wound healing assay, scale bar: 200 µm, n=3. F, G: ARPE-19 cells were pretreated with 20 µmol/L erlotinib for 12h and then treated with EGF (100 ng/mL) for 15min. Western blotting was used to detected EGFR/AKT signaling pathway proteins expressions. H, I: After pretreatment with 20 µmol/L erlotinib for 12h, ARPE-19 cells were treated with EGF (100 ng/mL) for 24h. N-cadherin, α-SMA and vimentin proteins were determined by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; α-SMA: α-smooth muscle actin; DAPI: Diamidino-2-phenylindole.

    Techniques Used: BrdU Staining, MTT Assay, Migration, Wound Healing Assay, Western Blot

    A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Figure Legend Snippet: A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Techniques Used: Control, Transfection, Western Blot, MTT Assay, Labeling, Migration, Wound Healing Assay, Small Interfering RNA

    A, B: After EGFR-siRNA transfections, ARPE-19 cells were treated without or with 100 ng/mL of EGF for 24h. N-cadherin, α-SMA and vimentin proteins were detected by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; APRE-19: Adult retinal pigment epithelial cell line-19; siRNA: Small interfering RNA; α-SMA: α-smooth muscle actin.
    Figure Legend Snippet: A, B: After EGFR-siRNA transfections, ARPE-19 cells were treated without or with 100 ng/mL of EGF for 24h. N-cadherin, α-SMA and vimentin proteins were detected by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; APRE-19: Adult retinal pigment epithelial cell line-19; siRNA: Small interfering RNA; α-SMA: α-smooth muscle actin.

    Techniques Used: Transfection, Western Blot, Small Interfering RNA

    egfr  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc egfr
    A) Immunoblot <t>against</t> <t>PTPRH</t> in H23, H23 KO, H23 KO in which various PTPRH constructs (WT or harboring point mutations) were added back, A427, and HT-29 cell lines. HT-29 is a colorectal carcinoma cell line overexpressing endogeneous PTPRH and it was used as a positive control. None of the PTPRH point mutations addbacks were used for the purpose of this paper. B) Log2 fold change of PTPRH mRNA expression in A427 (used as a reference sample), H23, H23 KO, and HT-29 cells (n=3/cell line). Replicates are represented as individual dots in the bar plot, and the mean+/− s.d. is shown. C) Annotated map of the PTPRH WT-HA plasmid. D) H23 cells and two H23 PTPRH KO clones (#2 and #13) were screened for differences in pEGFR 1173 (1197) levels after 15 of EGF (100 ng/mL) stimulation by immunoblot (n=3/cell line). Results of densitometry for pEGFR 1173 (1197)/total <t>EGFR</t> ratio for the replicates are demonstrated as individual dots in the bar plots (mean +/− s.d.). T-test was performed to compare the PTPRH KO group with the parental cell (H23) and *p<0.05 was considered a significant result. Abbreviations: IB = immunoblot
    Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2024-06
    86/100 stars

    Images

    1) Product Images from "Unravelling biological processess and EGFR pathway regulation by the receptor-like protein tyrosine phosphatase PTPRH in non-small cell lung cancer"

    Article Title: Unravelling biological processess and EGFR pathway regulation by the receptor-like protein tyrosine phosphatase PTPRH in non-small cell lung cancer

    Journal: bioRxiv

    doi: 10.1101/2024.06.13.598886

    A) Immunoblot against PTPRH in H23, H23 KO, H23 KO in which various PTPRH constructs (WT or harboring point mutations) were added back, A427, and HT-29 cell lines. HT-29 is a colorectal carcinoma cell line overexpressing endogeneous PTPRH and it was used as a positive control. None of the PTPRH point mutations addbacks were used for the purpose of this paper. B) Log2 fold change of PTPRH mRNA expression in A427 (used as a reference sample), H23, H23 KO, and HT-29 cells (n=3/cell line). Replicates are represented as individual dots in the bar plot, and the mean+/− s.d. is shown. C) Annotated map of the PTPRH WT-HA plasmid. D) H23 cells and two H23 PTPRH KO clones (#2 and #13) were screened for differences in pEGFR 1173 (1197) levels after 15 of EGF (100 ng/mL) stimulation by immunoblot (n=3/cell line). Results of densitometry for pEGFR 1173 (1197)/total EGFR ratio for the replicates are demonstrated as individual dots in the bar plots (mean +/− s.d.). T-test was performed to compare the PTPRH KO group with the parental cell (H23) and *p<0.05 was considered a significant result. Abbreviations: IB = immunoblot
    Figure Legend Snippet: A) Immunoblot against PTPRH in H23, H23 KO, H23 KO in which various PTPRH constructs (WT or harboring point mutations) were added back, A427, and HT-29 cell lines. HT-29 is a colorectal carcinoma cell line overexpressing endogeneous PTPRH and it was used as a positive control. None of the PTPRH point mutations addbacks were used for the purpose of this paper. B) Log2 fold change of PTPRH mRNA expression in A427 (used as a reference sample), H23, H23 KO, and HT-29 cells (n=3/cell line). Replicates are represented as individual dots in the bar plot, and the mean+/− s.d. is shown. C) Annotated map of the PTPRH WT-HA plasmid. D) H23 cells and two H23 PTPRH KO clones (#2 and #13) were screened for differences in pEGFR 1173 (1197) levels after 15 of EGF (100 ng/mL) stimulation by immunoblot (n=3/cell line). Results of densitometry for pEGFR 1173 (1197)/total EGFR ratio for the replicates are demonstrated as individual dots in the bar plots (mean +/− s.d.). T-test was performed to compare the PTPRH KO group with the parental cell (H23) and *p<0.05 was considered a significant result. Abbreviations: IB = immunoblot

    Techniques Used: Western Blot, Construct, Positive Control, Expressing, Plasmid Preparation, Clone Assay

    A) H23 and H23 PTPRH KO cells were stimulated with EGF (100 ng/mL) and cell lysates collected after 5, 15, 30, 60 and 120 minutes. Time point 0 represents non-stimulated (untreated) cells. Differences in pEGFR 1173 (1197) ( n =4/group in each time point) and pAKT S473 ( n =3/group in each time point) levels were assessed by immunoblot and representative blots are shown (mean +/− s.d.). Results of densitometry for pEGFR 1173 (1197)/total EGFR and pAKT/Total AKT ratio for the replicates are demonstrated as individual dots in the bar plots. T-test was performed to compare the PTPRH KO group with the parental cell (H23) in each time point and *p<0.05 was considered a significant result. B) EGFR was immunoprecipitated from H23 (n=2) and H23 PTPRH KO (n=3) cells stimulated with EGF (100 ng/mL) for 15 minutes and sent for mass spectrometry analysis. Quantitative values of normalized total precursor intensities for the identified phospho-Tyr sites in each cell line are represented in the table and the bar plot (mean +/− s.d.). Abbreviations: ns = non-significant; Tyr (Y) = tyrosine; IB = immunoblot
    Figure Legend Snippet: A) H23 and H23 PTPRH KO cells were stimulated with EGF (100 ng/mL) and cell lysates collected after 5, 15, 30, 60 and 120 minutes. Time point 0 represents non-stimulated (untreated) cells. Differences in pEGFR 1173 (1197) ( n =4/group in each time point) and pAKT S473 ( n =3/group in each time point) levels were assessed by immunoblot and representative blots are shown (mean +/− s.d.). Results of densitometry for pEGFR 1173 (1197)/total EGFR and pAKT/Total AKT ratio for the replicates are demonstrated as individual dots in the bar plots. T-test was performed to compare the PTPRH KO group with the parental cell (H23) in each time point and *p<0.05 was considered a significant result. B) EGFR was immunoprecipitated from H23 (n=2) and H23 PTPRH KO (n=3) cells stimulated with EGF (100 ng/mL) for 15 minutes and sent for mass spectrometry analysis. Quantitative values of normalized total precursor intensities for the identified phospho-Tyr sites in each cell line are represented in the table and the bar plot (mean +/− s.d.). Abbreviations: ns = non-significant; Tyr (Y) = tyrosine; IB = immunoblot

    Techniques Used: Western Blot, Immunoprecipitation, Mass Spectrometry

    A) Representation of the PTPRH domains and their location in the protein. The target region for deletion in each Δ construct is indicated by the blue bar. The table provides a complete description of the deletions and their position in the PTPRH protein. B) The generated constructs harboring deletions in either the PTPRH fibronectin3 domains or the phosphatase domain were aligned against the human PTPRH WT coding sequence. The red portions in the alignment represent the mismatch (deleted) regions. The arrows indicate positions where a single-nucleotide variation was found. Numbers represent the nucleotide position. C) Lung adenocarcinoma H23 (parental), H23 PTPRH KO, H23 PTPRH KO mock (control for lentivirus transduction), or H23 PTPRH KO cells in which PTPRH WT or various PTPRH deletions were added back to overexpress the protein were stimulated with EGF (100 ng/mL) for 15 min. The whole cell lysates ( n =3/group) were used to immunoblot pEGFR 1173 (1197), EGFR, B-actin, PTPRH, and HA-tag and the representative blot is shown. Densitometry results for pEGFR 1173 (1197)/total EGFR ratio for the replicates are demonstrated as individual dots in the bar plot, and the mean +/− s.d. is shown. T-test was performed to compare each group with the parental cell (H23) and *p<0.05 was considered a significant result. Abbreviations: FN3 = fibronectin3; ns = non-significant; IB = immunoblot; nt = nucleotide
    Figure Legend Snippet: A) Representation of the PTPRH domains and their location in the protein. The target region for deletion in each Δ construct is indicated by the blue bar. The table provides a complete description of the deletions and their position in the PTPRH protein. B) The generated constructs harboring deletions in either the PTPRH fibronectin3 domains or the phosphatase domain were aligned against the human PTPRH WT coding sequence. The red portions in the alignment represent the mismatch (deleted) regions. The arrows indicate positions where a single-nucleotide variation was found. Numbers represent the nucleotide position. C) Lung adenocarcinoma H23 (parental), H23 PTPRH KO, H23 PTPRH KO mock (control for lentivirus transduction), or H23 PTPRH KO cells in which PTPRH WT or various PTPRH deletions were added back to overexpress the protein were stimulated with EGF (100 ng/mL) for 15 min. The whole cell lysates ( n =3/group) were used to immunoblot pEGFR 1173 (1197), EGFR, B-actin, PTPRH, and HA-tag and the representative blot is shown. Densitometry results for pEGFR 1173 (1197)/total EGFR ratio for the replicates are demonstrated as individual dots in the bar plot, and the mean +/− s.d. is shown. T-test was performed to compare each group with the parental cell (H23) and *p<0.05 was considered a significant result. Abbreviations: FN3 = fibronectin3; ns = non-significant; IB = immunoblot; nt = nucleotide

    Techniques Used: Construct, Generated, Sequencing, Control, Transduction, Western Blot

    Cell lysates were immunoprecipitated (IP) for EGFR and immunoblotted (IB) for EGFR and PTPRH. Rabbit IgG antibody was used as a control isotype. A) Lung adenocarcinoma cells H23 or H23 PTPRH KO were stimulated with EGF (100 ng/mL) for 15 min. The whole cell lysate (WCL) of the colorectal cancer cell line HT29, which express high levels of PTPRH, was used as a positive control for IB, whereas H23 PTPRH KO cells were used as a negative control. B) H23 PTPRH KO cells in which PTPRH WT was added back were stimulated with EGF (100 ng/mL) at different time points (2, 5, 10, and 15 minutes) prior to cell lysis and IP. The same cell line was used for WCL positive control. Abbreviations: IB= immunoblot, IP= immunoprecipitation, m= minutes
    Figure Legend Snippet: Cell lysates were immunoprecipitated (IP) for EGFR and immunoblotted (IB) for EGFR and PTPRH. Rabbit IgG antibody was used as a control isotype. A) Lung adenocarcinoma cells H23 or H23 PTPRH KO were stimulated with EGF (100 ng/mL) for 15 min. The whole cell lysate (WCL) of the colorectal cancer cell line HT29, which express high levels of PTPRH, was used as a positive control for IB, whereas H23 PTPRH KO cells were used as a negative control. B) H23 PTPRH KO cells in which PTPRH WT was added back were stimulated with EGF (100 ng/mL) at different time points (2, 5, 10, and 15 minutes) prior to cell lysis and IP. The same cell line was used for WCL positive control. Abbreviations: IB= immunoblot, IP= immunoprecipitation, m= minutes

    Techniques Used: Immunoprecipitation, Control, Positive Control, Negative Control, Lysis, Western Blot

    A) Hierarchical clustering analysis of samples based on their normalized gene counts (rlog transformation). B) Normalized enrichment score (NES) plot of AKT_UP.V1_UP and EGFR_UP.V1_UP gene sets in PTPRH overexpression cell lines. C) MA plot of log2 fold change and mean of normalized counts.
    Figure Legend Snippet: A) Hierarchical clustering analysis of samples based on their normalized gene counts (rlog transformation). B) Normalized enrichment score (NES) plot of AKT_UP.V1_UP and EGFR_UP.V1_UP gene sets in PTPRH overexpression cell lines. C) MA plot of log2 fold change and mean of normalized counts.

    Techniques Used: Transformation Assay, Over Expression

    egfr monoclonal antibody  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc egfr monoclonal antibody
    Egfr Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr monoclonal antibody/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr monoclonal antibody - by Bioz Stars, 2024-06
    86/100 stars

    Images

    egfr py1068  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc egfr py1068
    Egfr Py1068, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr py1068/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr py1068 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    egfr 4267  (Cell Signaling Technology Inc)


    Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    Cell Signaling Technology Inc egfr 4267
    Egfr 4267, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr 4267/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr 4267 - by Bioz Stars, 2024-06
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86
    Cell Signaling Technology Inc egfr cell signalling 4267 1 1000
    Egfr Cell Signalling 4267 1 1000, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr cell signalling 4267 1 1000/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr cell signalling 4267 1 1000 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc anti p egfr tyr1068
    Anti P Egfr Tyr1068, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti p egfr tyr1068/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    anti p egfr tyr1068 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc egfr
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> <t>AKT</t> and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc phosphorylated egfr p egfr
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Phosphorylated Egfr P Egfr, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phosphorylated egfr p egfr/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    phosphorylated egfr p egfr - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc egfr monoclonal antibody
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Egfr Monoclonal Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr monoclonal antibody/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr monoclonal antibody - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc egfr py1068
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Egfr Py1068, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr py1068/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr py1068 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    86
    Cell Signaling Technology Inc egfr 4267
    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, <t>EGFR,</t> <t>p-EGFR,</t> AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.
    Egfr 4267, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/egfr 4267/product/Cell Signaling Technology Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    egfr 4267 - by Bioz Stars, 2024-06
    86/100 stars
      Buy from Supplier

    Image Search Results


    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Journal: International Journal of Ophthalmology

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    doi: 10.18240/ijo.2024.06.05

    Figure Lengend Snippet: ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Article Snippet: The EGFR, phosphorylated-EGFR (p-EGFR), AKT, phosphorylated-AKT (p-AKT), N-cadherin, α-smooth muscle actin (α-SMA), vimentin primary antibodies were from Cell Signaling Technology (Danvers, MA, USA).

    Techniques: MTT Assay, Labeling, Migration, Wound Healing Assay, Western Blot

    A, B: ARPE-19 cells were treated with erlotinib (0, 5, 10, 20, and 50 µmol/L) for 24h. The expreesion of total EGFR and AKT proteins were measured by Western blot. aP<0.05, bP<0.01. C: After treatment with 50 µmol/L erlotinib for 24h, EGFR, F-actin, and nucleus in ARPE-19 cells were measured by immunofluorescence staining, scale bar: 50 µm. APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; DAPI: Diamidino-2-phenylindole.

    Journal: International Journal of Ophthalmology

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    doi: 10.18240/ijo.2024.06.05

    Figure Lengend Snippet: A, B: ARPE-19 cells were treated with erlotinib (0, 5, 10, 20, and 50 µmol/L) for 24h. The expreesion of total EGFR and AKT proteins were measured by Western blot. aP<0.05, bP<0.01. C: After treatment with 50 µmol/L erlotinib for 24h, EGFR, F-actin, and nucleus in ARPE-19 cells were measured by immunofluorescence staining, scale bar: 50 µm. APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; DAPI: Diamidino-2-phenylindole.

    Article Snippet: The EGFR, phosphorylated-EGFR (p-EGFR), AKT, phosphorylated-AKT (p-AKT), N-cadherin, α-smooth muscle actin (α-SMA), vimentin primary antibodies were from Cell Signaling Technology (Danvers, MA, USA).

    Techniques: Western Blot, Immunofluorescence, Staining

    ARPE-19 cells were pretreated by erlotinib (20 µmol/L) for 12h and then stimulated with 100 ng/mL of EGF for 24h. A, B: BrdU staining assay was used to test cellular proliferation, scale bar: 50 µm, n=3. C: Cellular viability was sized by MTT assay, n=8. D, E: Cellular migration was tested by the wound healing assay, scale bar: 200 µm, n=3. F, G: ARPE-19 cells were pretreated with 20 µmol/L erlotinib for 12h and then treated with EGF (100 ng/mL) for 15min. Western blotting was used to detected EGFR/AKT signaling pathway proteins expressions. H, I: After pretreatment with 20 µmol/L erlotinib for 12h, ARPE-19 cells were treated with EGF (100 ng/mL) for 24h. N-cadherin, α-SMA and vimentin proteins were determined by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; α-SMA: α-smooth muscle actin; DAPI: Diamidino-2-phenylindole.

    Journal: International Journal of Ophthalmology

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    doi: 10.18240/ijo.2024.06.05

    Figure Lengend Snippet: ARPE-19 cells were pretreated by erlotinib (20 µmol/L) for 12h and then stimulated with 100 ng/mL of EGF for 24h. A, B: BrdU staining assay was used to test cellular proliferation, scale bar: 50 µm, n=3. C: Cellular viability was sized by MTT assay, n=8. D, E: Cellular migration was tested by the wound healing assay, scale bar: 200 µm, n=3. F, G: ARPE-19 cells were pretreated with 20 µmol/L erlotinib for 12h and then treated with EGF (100 ng/mL) for 15min. Western blotting was used to detected EGFR/AKT signaling pathway proteins expressions. H, I: After pretreatment with 20 µmol/L erlotinib for 12h, ARPE-19 cells were treated with EGF (100 ng/mL) for 24h. N-cadherin, α-SMA and vimentin proteins were determined by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; APRE-19: Adult retinal pigment epithelial cell line-19; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; α-SMA: α-smooth muscle actin; DAPI: Diamidino-2-phenylindole.

    Article Snippet: The EGFR, phosphorylated-EGFR (p-EGFR), AKT, phosphorylated-AKT (p-AKT), N-cadherin, α-smooth muscle actin (α-SMA), vimentin primary antibodies were from Cell Signaling Technology (Danvers, MA, USA).

    Techniques: BrdU Staining, MTT Assay, Migration, Wound Healing Assay, Western Blot

    A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Journal: International Journal of Ophthalmology

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    doi: 10.18240/ijo.2024.06.05

    Figure Lengend Snippet: A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Article Snippet: The EGFR, phosphorylated-EGFR (p-EGFR), AKT, phosphorylated-AKT (p-AKT), N-cadherin, α-smooth muscle actin (α-SMA), vimentin primary antibodies were from Cell Signaling Technology (Danvers, MA, USA).

    Techniques: Control, Transfection, Western Blot, MTT Assay, Labeling, Migration, Wound Healing Assay, Small Interfering RNA

    A, B: After EGFR-siRNA transfections, ARPE-19 cells were treated without or with 100 ng/mL of EGF for 24h. N-cadherin, α-SMA and vimentin proteins were detected by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; APRE-19: Adult retinal pigment epithelial cell line-19; siRNA: Small interfering RNA; α-SMA: α-smooth muscle actin.

    Journal: International Journal of Ophthalmology

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    doi: 10.18240/ijo.2024.06.05

    Figure Lengend Snippet: A, B: After EGFR-siRNA transfections, ARPE-19 cells were treated without or with 100 ng/mL of EGF for 24h. N-cadherin, α-SMA and vimentin proteins were detected by Western blot. aP<0.05, bP<0.01. EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; EMT: Epithelial-mesenchymal transition; APRE-19: Adult retinal pigment epithelial cell line-19; siRNA: Small interfering RNA; α-SMA: α-smooth muscle actin.

    Article Snippet: The EGFR, phosphorylated-EGFR (p-EGFR), AKT, phosphorylated-AKT (p-AKT), N-cadherin, α-smooth muscle actin (α-SMA), vimentin primary antibodies were from Cell Signaling Technology (Danvers, MA, USA).

    Techniques: Transfection, Western Blot, Small Interfering RNA

    ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Journal: International Journal of Ophthalmology

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    doi: 10.18240/ijo.2024.06.05

    Figure Lengend Snippet: ARPE-19 cells were stimulated by 100 ng/mL of EGF for 24h. A: The images of cells morphology were obtained after treatment, scale bar: 100 µm. B: Cellular viability was tested by the MTT assay, n=6. C, D: Cellular proliferation was analyzed by the BrdU labeling assay, scale bar: 50 µm, n=3. E, F: Cellular migration was measured by the wound healing assay, scale bar: 200 µm, n=3. G, H: After treatment with EGF (100 ng/mL) for 0, 0.25, 0.5, 1.0, 3.0, and 6.0h, EGFR, p-EGFR, AKT and p-AKT proteins in RPE cells were detected by Western blot assay. aP<0.05, bP<0.01. EGF: Epidermal growth factor; APRE-19: Adult retinalpigment epithelial cell line-19; EGFR: Epithelial growth factor receptor; AKT: Protein kinase B; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Article Snippet: The EGFR, phosphorylated-EGFR (p-EGFR), AKT, phosphorylated-AKT (p-AKT), N-cadherin, α-smooth muscle actin (α-SMA), vimentin primary antibodies were from Cell Signaling Technology (Danvers, MA, USA).

    Techniques: MTT Assay, Labeling, Migration, Wound Healing Assay, Western Blot

    A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Journal: International Journal of Ophthalmology

    Article Title: Inhibition of EGFR attenuates EGF-induced activation of retinal pigment epithelium cell via EGFR/AKT signaling pathway

    doi: 10.18240/ijo.2024.06.05

    Figure Lengend Snippet: A, B: After EGFR-siRNA or control-siRNA were transfected into ARPE-19 cells, EGFR and AKT proteins were tested and analyzed by Western blotting. After EGFR-siRNA transfection, ARPE-19 cells were treated without or with 100 ng/mL EGF for 24h. C: Cellular viability was tested by MTT assay, n=8. D, E: Cellular proliferation was tested by the BrdU labeling assay, scale bar: 50 µm, n=3. F, G: Cellular migration was detected by the wound healing assay, scale bar: 200 µm, n=3. H, I: After transfected by control-siRNA or EGFR-siRNA, ARPE-19 cells were stimulated without or with 100 ng/mL of EGF for 15min. EGFR, p-EGFR, AKT and p-AKT protein were detected by Western blot. aP<0.05, bP<0.01. siRNA: Small interfering RNA; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor; AKT: Protein kinase B; APRE-19: Adult retinal pigment epithelial cell line-19; MTT: Methyl thiazolyl tetrazolium; BrdU: 5-Bromodeoxyuridinc; DAPI: Diamidino-2-phenylindole.

    Article Snippet: The EGFR, phosphorylated-EGFR (p-EGFR), AKT, phosphorylated-AKT (p-AKT), N-cadherin, α-smooth muscle actin (α-SMA), vimentin primary antibodies were from Cell Signaling Technology (Danvers, MA, USA).

    Techniques: Control, Transfection, Western Blot, MTT Assay, Labeling, Migration, Wound Healing Assay, Small Interfering RNA